Infinity Bio Launches MuSIGHT™ Mouse Autoantibody Reactome Service to Advance Immune Health Research
Infinity Bio is proud to announce the launch of its groundbreaking MuSIGHT™ mouse autoantibody reactome service. This new service represents a significant leap forward in understanding the immune system by offering an in-depth analysis of animal autoantibody reactomes—key insights into immune health and inflammatory responses. Powered by Infinity Bio’s proprietary MIPSA technology, the MuSIGHT™ service promises the most comprehensive antibody analyses available, with fast turnaround times and full downstream informatics support.
In this article, we will explore the implications of this new service, its key features, and how it will aid researchers working on mouse models of human diseases.
Understanding the Mouse Autoantibody Reactome
The autoantibody reactome refers to the complete set of interactions between host proteins and antibodies within an organism. These interactions are crucial for understanding an animal’s immune health, inflammatory status, and overall immune system function. By defining the mouse autoantibody reactome, researchers can better characterize various disease mechanisms, assess immune responses, and pinpoint targets for therapeutic interventions.
With the MuSIGHT™ service, Infinity Bio offers an essential tool to researchers, particularly those working with animal models of human diseases, to gain deeper insights into the immune landscape of their models. As Ben Larman, Ph.D., the founder and Chief Science Officer of Infinity Bio, explains, “This technology can now be used to discover immune targets in cancers, clarify the contribution of autoimmunity in inflammatory diseases, and illuminate the role of the immune system in healthy aging.”
Advanced Technology: MIPSA
Infinity Bio’s proprietary MIPSA (Mouse ImmunoProteomics System Analysis) technology powers the MuSIGHT™ service, providing highly detailed, reliable, and reproducible data. MIPSA enables Infinity Bio to analyze a vast range of antibody-protein interactions, allowing researchers to identify and map the full extent of immune responses in mice.
This advanced technology ensures that Infinity Bio can offer the most comprehensive antibody analyses currently available, with fast turnaround times that are crucial for time-sensitive research. Furthermore, MuSIGHT™ comes with robust downstream informatics support, ensuring that researchers can leverage this data to its fullest potential.
The Mouse Proteome and Its Relevance to Disease Research
The mouse proteome, which is composed of approximately 176,000 unique protein isoforms, serves as the foundation of MuSIGHT™. Infinity Bio’s advanced peptide design algorithm has been used to align and tile the proteome, ensuring a comprehensive and accurate representation of the entire set of proteins in a mouse model. The library includes not only these isoforms but also 2,164 processed and secreted protein products displayed in their mature forms.
According to Joy Nassif, CEO of Infinity Bio, “This carefully designed library of 273,786 peptides is the most complete representation of the mouse proteome created to date. We are excited to empower researchers to better understand their animal models. MuSIGHT™ will illuminate the relationship between these models and the human diseases they are meant to represent.”
By providing a more complete understanding of the mouse proteome, the MuSIGHT™ service enables researchers to draw more accurate and reliable parallels between animal models and human diseases. This is particularly important for translating preclinical findings into clinical insights, a challenge that often hinders the progress of medical research.
Addressing the Limitations of Animal Models
Animal models, especially mice, have long been a cornerstone of biomedical research, especially for studying human diseases. However, there is a well-documented gap between preclinical results in animals and the success of clinical trials in humans. One major factor contributing to this discrepancy is the differing immune processes between species.
For instance, while mice are often used to model human cancers and autoimmune diseases, their immune systems are not identical to those of humans, which can lead to limited translatability of findings. MuSIGHT™ addresses this challenge by offering a more precise and comprehensive view of murine immune processes, particularly in the context of autoimmunity and anti-cancer immunity.
By providing a clearer understanding of how the mouse immune system responds to disease and therapeutic interventions, Infinity Bio’s MuSIGHT™ service enables researchers to refine their animal models, making them more accurate representations of human conditions. This, in turn, can help bridge the gap between preclinical and clinical research.
Enhancing Immunotherapy and Autoimmunity Research
The MuSIGHT™ service opens new avenues for researchers working on immunotherapies and autoimmune diseases. The ability to map and analyze autoantibody interactions within mouse models provides researchers with a powerful tool to discover immune targets, understand disease mechanisms, and identify potential therapeutic candidates.
In cancer research, for example, understanding how antibodies interact with the mouse immune system can reveal key immune targets that can be leveraged in the development of immunotherapies. Similarly, by examining autoimmune responses, researchers can uncover novel pathways for diagnosing and treating inflammatory diseases.
Commitment to Quality and Customer Experience
At Infinity Bio, data quality and customer experience are paramount. Joy Nassif, the company’s CEO, emphasizes, “We pride ourselves on unmatched data quality, reliability, and customer experience. It is our mission to provide industry-leading antibody reactome services to biomedical researchers around the world.” The MuSIGHT™ service exemplifies this commitment by offering highly reliable data, cutting-edge technology, and comprehensive support to researchers.
Infinity Bio’s dedication to advancing scientific research is reflected not only in the quality of its services but also in the company’s broader mission to empower scientists in their efforts to address some of the world’s most pressing health challenges.
Conclusion
The launch of Infinity Bio’s MuSIGHT™ mouse autoantibody reactome service marks a major milestone in immune health research. By providing a comprehensive and detailed analysis of mouse autoantibody interactions, MuSIGHT™ gives researchers the tools they need to explore the immune systems of their animal models with unprecedented accuracy. With its advanced MIPSA technology, extensive peptide library, and commitment to data quality, Infinity Bio is poised to revolutionize how scientists approach immunology, cancer research, autoimmunity, and more.
By improving our understanding of immune processes in mouse models, Infinity Bio is helping researchers bridge the gap between preclinical studies and human clinical trials, ultimately accelerating the development of new treatments for a range of diseases.
About Infinity Bio
Infinity Bio, Inc. is a technology company that provides detailed insights into the immune system using its proprietary antibody reactome profiling platform. The company’s core technology, MIPSA, is used to comprehensively analyze the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Developed at Johns Hopkins University in The Laboratory of Precision Immunology, MIPSA builds on decades of work in genomics, proteomics, immunology, and bioinformatics. Infinity Bio’s assays are engineered to enable best-in-class quality, data accuracy, turnaround times and cost-efficiency. For more information, visit www.infinitybio.com.
